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The human papillomavirus type 16/18 (HPV-16/18) AS04-adjuvanted cervical cancer vaccine is licensed for
females aged 10 years and above and is therefore likely to be coadministered with other licensed vaccines, such
as hepatitis B. In this randomized, open-label study, we compared the immunogenicity of the hepatitis B
vaccine administered alone (HepB group) or with the HPV-16/18 AS04-adjuvanted vaccine (HepBHPV
group) in healthy women aged 20 to 25 years (clinical trial NCT00637195). The hepatitis B vaccine was given
at 0, 1, 2, and 12 months (an accelerated schedule which may be required by women at high risk), and the
HPV-16/18 vaccine was given at 0, 1, and 6 months. One month after the third dose of hepatitis B vaccine, in
the according-to-protocol cohort (n  72 HepBHPV; n  76 HepB), hepatitis B seroprotection rates (titer of
>10 mIU/ml) were 96.4% (95% confidence interval [CI], 87.5 to 99.6) and 96.9% (CI, 89.2 to 99.6) in the
HepBHPV and HepB groups, respectively, in women initially seronegative for anti-hepatitis B surface antigen
(HBs) and anti-hepatitis B core antigen (HBc). Corresponding geometric mean titers of anti-HBs antibodies
were 60.2 mIU/ml (CI, 40.0 to 90.5) and 71.3 mIU/ml (CI, 53.9 to 94.3). Anti-HBs antibody titers rose
substantially after the fourth dose of hepatitis B vaccine. All women initially seronegative for anti-HPV-16 and
anti-HPV-18 antibodies seroconverted after the second HPV-16/18 vaccine dose and remained seropositive up
to 1 month after the third dose. Both vaccines were generally well tolerated, with no difference in reactogenicity
between groups. In conclusion, coadministration of the HPV-16/18 AS04-adjuvanted vaccine did not affect the
immunogenicity or safety of the hepatitis B vaccine administered in an accelerated schedule in young women.
Hepatitis B is a serious disease that can be fatal or lead to
chronic liver disease, including hepatocellular carcinoma and
liver cirrhosis. Approximately 2 billion people worldwide are
infected with the hepatitis B virus (HBV), of whom approxi-
mately 350 million are currently suffering from a chronic HBV
infection (30). About 1 million of these chronically infected
patients die each year of HBV-related liver disease (30).
The World Health Organization (WHO) recommends in-
tegration of hepatitis B vaccination into national infant im-
munization programs, and 92% of countries had included
the vaccine in routine immunization programs by 2008
(www.who.int/immunization_monitoring/diseases/hepatitis/en
/index.html). However, some northern European countries with
low carrier rates offer vaccination only to high-risk groups (35).
The standard schedule for vaccination against hepatitis B con-
sists of three doses given at 0, 1, and 6 months. Where rapid
protection is required (e.g., in high-risk groups or travelers), an
accelerated schedule of either 0, 1, and 2 months or 0, 7, and
21 days can be adopted (28). Both of these schedules require a
fourth vaccine dose at 1 year after the first administration.
A number of hepatitis B vaccines are currently on the
market, both as single-antigen formulations and in combi-
nation with other antigens (18, 19). They are widely used in
routine immunization programs as well as for travelers and
high-risk groups. The recombinant hepatitis B vaccine from
GlaxoSmithKline (GSK) Biologicals has been available
since the mid-1980s; it is well tolerated, with high immuno-
genicity and protective efficacy, offering protection for up to
20 years (25). In addition, it can be administered in a variety
of vaccination schedules, providing considerable flexibility.
Cervical cancer is the second most common cancer in
women worldwide (7). Human papillomavirus (HPV) infection
is well established as the necessary cause of the disease (36).
Fifteen HPV types have been identified as oncogenic (20), with
HPV-16 and HPV-18 being the two most frequent types, as-
sociated with approximately 70% of cervical cancer cases
worldwide (2).
Two HPV vaccines are currently available, an HPV-16/18
vaccine from GSK Biologicals and an HPV-6/11/16/18 vaccine
from Merck & Co. Extensive clinical trial programs of both
vaccines have shown that they are highly immunogenic, pro-
vide protection against vaccine and some nonvaccine onco-
genic HPV types (cross-protection) together with associated
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cytohistological lesions, and are generally well tolerated (3, 5,
8, 12, 21, 23, 29, 32). The HPV-16/18 cervical cancer vaccine
from GSK Biologicals is formulated with the Adjuvant System
AS04 (comprising aluminum hydroxide and 3-O-desacyl-4
monophosphoryl lipid A) (10). The AS04-adjuvanted vaccine
produces a greater immune response, with higher and more
sustained antibody titers and a higher frequency of memory
B-cells, than HPV vaccines adjuvanted with aluminum (6, 11).
It is likely that some young women will need to receive the
HPV-16/18 vaccine and the hepatitis B vaccine at the same
time. Those at high risk of hepatitis B infection, such as trav-
elers to areas of endemicity, drug users, or sex workers, will
probably receive the vaccine in an accelerated schedule. The
objectives of the present study were to evaluate the immuno-
genicity and safety of the hepatitis B vaccine from GSK Bio-
logicals in an accelerated schedule when the vaccine is coad-
ministered with the HPV-16/18 vaccine. The immune response
after the third dose of the hepatitis B vaccine administered in
the approved accelerated schedule was the main point of in-
terest in this study, as vaccination against hepatitis B requires
at least three vaccine doses to reach optimal levels of seropro-
tection.
MATERIALS AND METHODS
Study objectives. The primary objective was to evaluate the immune response
against HBV in terms of seroprotection rate and geometric mean titers (GMTs)
1 month after the third dose of the hepatitis B vaccine (at month 3 of the study).
Secondary objectives included evaluation of the immune response against HBV
in terms of seroconversion rate, seroprotection rate, and GMTs after the second,
third (seroconversion rate only), and fourth hepatitis B vaccine doses; the im-
mune response against HPV-16 and HPV-18 after the second and third HPV-
16/18 vaccine doses; and reactogenicity and safety of the vaccines administered.
Study design and participants. This was a phase IIIb, randomized, controlled,
open-label study with two parallel treatment groups, conducted in two study
centers in Belgium (clinical trial NCT00637195). The study included an active
phase (month 0 to month 7), with a follow-up phase to month 13 (Fig. 1).
Healthy women aged 20 to 25 years were included in the study. Women were
excluded if they had received immunosuppressive or other immune-modifying
drugs for more than 14 days within the previous 6 months or had a history of
hepatitis B infection, exposure to hepatitis B within the previous 6 weeks before
the start of the study, or previous vaccination against hepatitis B; they were also
excluded if they had any immunosuppressant or immunodeficient condition,
cancer or autoimmune disease, history of allergic disease likely to be exacerbated
by a vaccine component, known acute or chronic clinically significant neurologic,
hepatic or renal functional abnormality, or acute disease at enrollment. Women
were required to use adequate contraceptive methods and must not have been
pregnant or breastfeeding.
Women were randomized (1:1 ratio) to receive the hepatitis B vaccine given at
0, 1, 2, and 12 months and the HPV-16/18 vaccine given at 0, 1, and 6 months
(HepBHPV group) or the hepatitis B vaccine alone given at 0, 1, 2, and 12
months (HepB group) (Fig. 1). A randomization blocking scheme was used, with
the randomization list generated at GSK Biologicals using a standard Statistical
Analysis System (SAS) program. Treatment allocation at each study center was
performed using an Internet-based randomization system with an algorithm
using a minimization procedure accounting for center.
Both the hepatitis B and HPV vaccines were supplied by GSK Biologicals,
Belgium. Each dose of the hepatitis B vaccine (Engerix-B) consisted of 20 g
of hepatitis B surface antigen (HBsAg) produced by recombinant yeast cells
(Saccharomyces cerevisiae), formulated with 500 g of aluminum salt. Each dose
of the HPV-16/18 vaccine (Cervarix) consisted of 20 g each of HPV-16 and
HPV-18 L1 proteins, self-assembled as virus-like particles (VLPs) and formu-
lated with the Adjuvant System AS04 (comprising 500 g of aluminum hydroxide
and 50 g of the immunostimulatory molecule 3-O-desacyl-4 monophosphoryl
lipid A). Both vaccines were supplied as individual prefilled syringes (1 ml per
dose for the hepatitis B vaccine and 0.5 ml per dose for the HPV-16/18 vaccine)
and were to be administered intramuscularly into the deltoid muscle of the
nondominant arm, except when the HPV-16/18 vaccine and the hepatitis B
vaccine were coadministered, in which case the hepatitis B vaccine was admin-
istered in the dominant arm.
The study was conducted in accordance with the Declaration of Helsinki
FIG. 1. Study design. M, month.
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(1996) and the International Conference on Harmonisation Good Clinical Prac-
tice guidelines. The protocol and informed consent forms were approved by the
Independent Ethics Committee or Institutional Review Board of each study
center. Written informed consent was obtained from each woman. At the end of
the study, vaccination with the HPV-16/18 AS04-adjuvanted vaccine was offered
to all women in the HepB group.
Study procedures. (i) Immunogenicity. Blood samples were collected at
months 0, 2, 3, 7, and 13 in the HepBHPV group and at months 0, 2, 3, and 13
in the HepB group (Fig. 1). Hepatitis B-related antibodies (anti-HBs and anti-
hepatitis B core antigen [HBc]) were measured in both study groups. Anti-HBs
antibodies were measured by enzyme-linked immunosorbent assay (ELISA) at
months 0, 2, 3, and 13 (4). Seroconversion was defined as an antibody concen-
tration of 3.3 mIU/ml (the assay threshold) in women who were seronegative
at baseline; seroprotection was defined as an antibody concentration of 10
mIU/ml. Anti-HBc antibodies were measured qualitatively (present or absent) by
a microparticle enzyme immunoassay (MEIA; Axsym Core/Abbott Laborato-
ries) at month 0. Anti-HPV-16 and anti-HPV-18 antibodies were measured by
ELISA using type-specific VLPs as coating antigens (serum-standardized proto-
col as previously published [22, 27]) at months 0, 2, 3, and 7 in the HepBHPV
study group. Seroconversion was defined as a titer of 8 ELISA units (EU)/ml
for anti-HPV-16 and 7 EU/ml for anti-HPV-18 (the assay thresholds) in
women who were seronegative at baseline.
(ii) Reactogenicity and safety. Solicited adverse events (AEs) occurring within
7 days after each vaccination were recorded on diary cards. Solicited local AEs
included pain, redness, and swelling. Solicited general AEs included fever, head-
ache, fatigue, gastrointestinal symptoms (nausea, vomiting, diarrhea, and abdom-
inal pain), arthralgia, myalgia, rash, and urticaria. In addition to diary card data,
urticaria or rash that appeared within 30 min of each vaccine dose was recorded
by the investigator. The greatest surface diameters of areas of redness or swelling
were recorded. Fever was defined as an oral/axillary temperature of37.5°C. All
other solicited AEs were graded on a scale of 0 to 3. Grade 3 events were defined
as preventing normal activity, an area of redness or swelling of 50 mm, or
temperature of 39°C. Unsolicited AEs were reported from day 0 to day 29 after
each vaccination. All solicited local AEs were considered related to vaccination.
Investigators assessed the likely causality of all other AEs.
Serious adverse events (SAEs), medically significant conditions, new-onset
chronic diseases (NOCDs), new-onset autoimmune disorders (NOADs), and
pregnancies and their outcomes were recorded throughout the study. Medically
significant conditions were defined as AEs prompting either emergency room
visits or physician visits that were not routine or related to common diseases or
as SAEs that were not related to common diseases. Based on a prespecified list,
the clinical database was searched for all potential NOCDs and reviewed in a
blind manner by a GSK physician prior to data analysis. An event was considered
to be a potential NOCD if it had not been recorded in the previous medical
history of the subject (i.e., new onset) and/or if symptoms were characteristic of
an NOCD. A separate list, restricted to potential autoimmune events, was also
used by a GSK safety physician to identify NOADs.
Statistics and endpoints. The primary endpoints of the study were seropro-
tection rates and GMTs for anti-HBs antibodies 1 month after the third dose of
the hepatitis B vaccine. Secondary endpoints were as follows: (i) seroconversion
rates and GMTs for anti-HPV-16 and anti-HPV-18 antibodies 1 month after the
second and third doses of the HPV-16/18 vaccine; (ii) seroconversion rates for
anti-HBs antibodies 1 month after the third dose of the hepatitis B vaccine; (iii)
seroconversion rates, seroprotection rates, and GMTs for anti-HBs antibodies 1
month after the second and fourth doses of the hepatitis B vaccine; and (iv)
occurrence of solicited and unsolicited AEs, SAEs, and medically significant
conditions.
A sample size of 70 evaluable women in the HepBHPV group was needed
to show with at least 80% power that the seroprotection rate at month 3 for
anti-HBs antibodies was not less than 90% (assuming a seroprotection rate of
98%). The power calculation was based on a two-sided exact test for one bino-
mial proportion with an alpha of 5% using the Power Analysis and Sample Size
(PASS) 2005 program. It was assumed that 8% of women may be unevaluable at
month 3 due to withdrawals, seropositivity at baseline, or other reasons, and
therefore a total of 76 women per group were to be enrolled.
The primary analysis of anti-HBs and anti-HPV antibodies was conducted in
the according-to-protocol (ATP) cohort for the active phase of the study (ATP
active-phase). This cohort included women who met all eligibility criteria and
complied with the protocol up to month 7 of the study. Data are also reported for
anti-HBs antibodies following the fourth dose of hepatitis B vaccine in a second
ATP cohort (ATP HepB fourth-dose) which included women who met all eligi-
bility criteria and complied with the protocol up to month 13.
Seroconversion rates and seroprotection rates with exact 95% confidence
intervals (CI) and GMTs with 95% CI for anti-HBs were calculated in women
with undetectable anti-HBs and anti-HBc titers at baseline. Seroconversion rates
with exact 95% CI and GMTs with 95% CI for anti-HPV-16 and anti-HPV-18
were calculated according to prevaccination status (i.e., seropositive or serone-
gative at baseline for the corresponding HPV type). The 95% CI for GMTs was
obtained within each group separately. The 95% CI for the mean of log-trans-
formed titer was first obtained assuming that log-transformed values were nor-
mally distributed with unknown variance. The 95% CI for the GMTs was then
obtained by exponential transformation of the 95% CI for the mean of log-
transformed titer. The exact 95% CI for a proportion within a group was calcu-
lated from Proc StatXact.
Solicited and unsolicited symptoms following the first three doses of each
vaccine (i.e., up to month 7) are reported for the total vaccinated cohort (TVC
active-phase). The cohort included all women who had at least one vaccine dose
documented for unsolicited symptoms. Solicited and unsolicited symptoms fol-
lowing the fourth dose of hepatitis B vaccine are reported for the TVC up to
month 13 (TVC HepB fourth-dose). The cohort included all women who re-
ceived the fourth hepatitis B vaccine dose at month 12. Serious adverse events,
medically significant AEs, NOCDs, and NOADs occurring throughout the study
are also reported for this cohort. Data were analyzed descriptively. The exact
95% CI for a proportion within a group was calculated from Proc StatXact.
RESULTS
The first woman was enrolled in March 2008, and the last
visit of the last study participant took place in June 2009. A
total of 152 women were enrolled, 76 in each group. All were
vaccinated and comprised the TVC active-phase (Fig. 2). The
ATP active-phase cohort included 72 women in the
HepBHPV group and 76 women in the HepB group. Rea-
sons for exclusion are shown in Fig. 2. A total of 74 women in
the HepBHPV group and 75 women in the HepB group
received the fourth hepatitis B vaccine dose and comprised the
TVC HepB fourth-dose cohort; 69 and 75 women comprised
the ATP HepB fourth-dose cohort in the HepBHPV and
HepB groups, respectively (Fig. 2). A total of 73 and 75 women
completed the study to month 13 in the HepBHPV and
HepB groups, respectively.
The mean (standard deviation) age of the women was 22.2
(1.42) years in the TVC active-phase, and most (96.7%) were
of white Caucasian/European heritage. Demographic charac-
teristics were similar in the other cohorts and between groups.
Immunogenicity: anti-HB antibodies. Seventeen women
(23.6%) in the HepBHPV group and 11 women (14.5%) in the
HepB group were already seropositive for anti-HBs antibodies
before vaccination. Ten (13.9%) and seven (9.2%) women were
seroprotected before vaccination. One participant in the HepB
group was seropositive for anti-HBc antibodies. In women who
were seronegative for both anti-HBs and anti-HBc before vacci-
nation, seroprotection rates were 96.4% (95% CI, 87.5 to 99.6)
and 96.9% (95% CI, 89.2 to 99.6) in the HepBHPV and HepB
groups, respectively, at month 3, i.e., 1 month after the third dose
of hepatitis B vaccine (a coprimary endpoint) (Table 1). High
rates of seroconversion and seroprotection were also seen at
other time points (Table 1).
Geometric mean titers at month 3 (a coprimary endpoint)
were similar in both study groups: 60.2 mIU/ml (95% CI, 40.0
to 90.5) in the HepBHPV group and 71.3 mIU/ml (95% CI,
53.9 to 94.3) in the HepB group (Fig. 3). Titers rose more than
200-fold after the fourth dose of hepatitis B vaccine to 17,416.7
mIU/ml (95% CI, 10,294.3 to 29,466.9) and 14,470.2 mIU/ml
(95% CI, 9,824.6 to 21,312.4) in the HepBHPV and HepB
groups, respectively (Fig. 3).
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Immunogenicity: anti-HPV-16 and anti-HPV-18 antibodies.
Before vaccination, 87.3% and 94.4% of women were serone-
gative for HPV-16 and HPV-18, respectively. All initially se-
ronegative women had seroconverted for both HPV-16 and
HPV-18 at 1 month after the second vaccine dose (month 2)
and remained seropositive at 1 month after the third dose
(month 7). One month after the third vaccination, GMTs were
9,217.9 EU/ml (95% CI, 7,396.6 to 11,487.7) for anti-HPV-16
antibodies and 4,726.8 EU/ml (95% CI, 3,718.5 to 6,008.4) for
anti-HPV-18 antibodies in women seronegative at baseline for
the corresponding HPV type (Fig. 4).
Reactogenicity and safety. (i) Reactogenicity following the
first three doses of each vaccine. Overall, solicited symptoms
(local and general) were reported during the 7-day postvacci-
nation period following 83.5% of all vaccine doses during the
active phase of the study (the first three hepatitis B vaccine
doses and all three HPV-16/18 vaccine doses) in the
HepBHPV group. Grade 3 solicited symptoms were re-
FIG. 2. Subject disposition.
TABLE 1. Seroconversion and seroprotection rates for anti-HBs antibodies in women initially seronegative before vaccinationa
Antibody titer group and time point
HepBHPV group HepB group
No. of women Rate (% 95% CI) No. of women Rate (% 95% CI)
Seroconversion (titer 3.3 mIU/ml)
Prevaccination 55 0.0 (0.0–6.5) 64 0.0 (0.0–5.6)
Month 2 55 83.6 (71.2–92.2) 64 84.4 (73.1–92.2)
Month 3 55 100 (93.5–100) 64 98.4 (91.6–100)
Month 13 52 100 (93.2–100) 63 100 (94.3–100)
Seroprotection (titer 10 mIU/ml)
Prevaccination 55 0.0 (0.0–6.5) 64 0.0 (0.0–5.6)
Month 2 55 58.2 (44.1–71.3) 64 70.3 (57.6–81.1)
Month 3 55 96.4 (87.5–99.6) 64 96.9 (89.2–99.6)
Month 13 52 100 (93.2–100) 63 100 (94.3–100)
a Data are from women who were seronegative for anti-HBs and anti-HBc before vaccination. Data are shown for the ATP active-phase cohort for the prevaccination,
month 2, and month 3 time points and for the ATP HepB fourth-dose cohort for the month 13 time point.
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ported after 4.0% of doses in this group. In the HepB group,
solicited symptoms were reported after 76.1% of doses during
the 7-day postvaccination period; grade 3 solicited symptoms
were reported after 6.6% of doses.
The incidences of solicited local symptoms at the hepatitis B
vaccination site were similar regardless of coadministration of
the HPV-16/18 vaccine. Pain at the injection site was the most
frequent solicited local symptom, reported at the hepatitis B
vaccine injection site after 53.9% of doses in the HepBHPV
group and after 58.4% of doses in the HepB group (Table 2).
FIG. 3. Seroprotection rates (values above the bars) and GMTs (values inside the bars) for anti-HBs antibodies in women initially seronegative
before vaccination. Data are shown for the ATP active-phase cohort for prevaccination, month 2, and month 3 time points and for the ATP HepB
fourth-dose cohort at the month 13 time point.
FIG. 4. Seroconversion rates (values above the bars) and GMTs (values inside the bars) for anti-HPV-16 (A) and anti-HPV-18 (B) antibodies
in women initially seronegative before vaccination (ATP active-phase cohort, HepBHPV group).
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Pain was experienced more frequently at the HPV-16/18 vac-
cine injection site, reported after 89.0% of doses (Table 2).
Redness and swelling also occurred less often at the hepatitis
B vaccine injection site than at the HPV-16/18 vaccine injec-
tion site (Table 2). Few grade 3 local symptoms occurred at
either injection site (Table 2). In the HepBHPV group,
grade 3 pain occurred following 0.4% of doses at the hepatitis
B vaccine injection site and following 3.1% of doses at the
HPV-16/18 vaccine injection site. In the HepB group, grade 3
pain occurred following 0.9% of doses.
The incidences of solicited general symptoms reported on
diary cards were also similar regardless of coadministration of
the HPV-16/18 vaccine (Table 3). Fatigue was the most com-
mon solicited general symptom, occurring after 38.6% and
42.5% of vaccine doses in the HepBHPV group and the
HepB group, respectively. Grade 3 solicited general symptoms
occurred rarely (Table 3). There were no grade 3 cases of
arthralgia, rash, or urticaria reported on diary cards. Only one
case of urticaria/rash was reported by the investigator within 30
min of vaccination, in a woman in the HepBHPV group.
The percentage of doses followed by an unsolicited AE
within 30 days of vaccination was 33.7% (95% CI, 28.4 to 39.3)
in the HepBHPV group and 31.6% (95% CI, 25.6 to 38.0) in
the HepB group. The most common unsolicited symptom was
headache, occurring after 6.3% of doses in the HepBHPV
group and 7.0% in the HepB group. Overall, 5.6% and 4.8% of
vaccine doses in the HepBHPV and HepB groups, respec-
tively, were followed by unsolicited AEs considered related to
vaccination.
(ii) Reactogenicity following the fourth dose of hepatitis B
vaccine. Table 4 shows the percentage of women who reported
a solicited local or general symptom on their diary cards within
the 7-day period following the fourth dose of hepatitis B vac-
cine. In addition, one potential case of investigator-reported
urticaria within the first 30 min following vaccination was sus-
pected in the HepBHPV group. Reactogenicities were sim-
ilar in both study groups and comparable with findings follow-
ing the first three doses of vaccine.
The percentage of women reporting an unsolicited AE
within 30 days of vaccination was 27.0% (95% CI, 17.4 to
38.6%) in the HepBHPV group and 29.3% (95% CI, 19.4 to
41.0%) in the HepB group. The most common events were
cystitis and oropharyngeal pain. Unsolicited symptoms consid-
ered related to vaccination were reported by 4.1% and 12.0%
of women in the HepBHPV and HepB groups, respectively.
TABLE 2. Percentage of vaccine doses followed by a solicited local symptom during the 7-day postvaccination perioda
Symptom
and grade
HepBHPV group
HepB group (n  226)b
HepB (n  228)b HPV-16/18 (n  227)b
No. of doses % of doses (95% CI) No. of doses % of doses (95% CI) No. of doses % of doses (95% CI)
Pain
All 123 53.9 (47.2–60.5) 202 89.0 (84.2–92.7) 132 58.4 (51.7–64.9)
Grade 3 1 0.4 (0.0–2.4) 7 3.1 (1.2–6.3) 2 0.9 (0.1–3.2)
Redness
All 23 10.1 (6.5–14.8) 44 19.4 (14.5–25.1) 20 8.8 (5.5–13.3)
Grade 3 0 0.0 (0.0–1.6) 0 0.0 (0.0–1.6) 0 0.0 (0.0–1.6)
Swelling
All 14 6.1 (3.4–10.1) 43 18.9 (14.1–24.7) 14 6.2 (3.4–10.2)
Grade 3 1 0.4 (0.0–2.4) 2 0.9 (0.1–3.1) 1 0.4 (0.0–2.4)
a Includes the first three doses of HepB vaccine and all three doses of HPV-16/18 vaccine; TVC active phase.
b n, total number of doses.
TABLE 3. Percentage of vaccine doses followed by a solicited
general symptom during the 7-day postvaccination perioda
Symptom and
grade
HepBHPV group
(n  303)b
HepB group
(n  226)b
No. of
doses
% of doses
(95% CI)
No. of
doses
% of doses
(95% CI)
Arthralgia
All 11 3.6 (1.8–6.4) 14 6.2 (3.4–10.2)
Grade 3 0 0.0 (0.0–1.2) 0 0.0 (0.0–1.6)
Fatigue
All 117 38.6 (33.1–44.4) 96 42.5 (35.9–49.2)
Grade 3 3 1.0 (0.2–2.9) 5 2.2 (0.7–5.1)
Fever
All 10 3.3 (1.6–6.0) 5 2.2 (0.7–5.1)
Grade 3 0 0.0 (0.0–1.2) 1 0.4 (0.0–2.4)
Gastrointestinal
All 33 10.9 (7.6–15.0) 42 18.6 (13.7–24.3)
Grade 3 1 0.3 (0.0–1.8) 5 2.2 (0.7–5.1)
Headache
All 90 29.7 (24.6–35.2) 70 31.0 (25.0–37.4)
Grade 3 1 0.3 (0.0–1.8) 7 3.1 (1.3–6.3)
Myalgia
All 41 13.5 (9.9–17.9) 48 21.2 (16.1–27.2)
Grade 3 0 0.0 (0.0–1.2) 2 0.9 (0.1–3.2)
Rash
All 3 1.0 (0.2–2.9) 7 3.1 (1.3–6.3)
Grade 3 0 0.0 (0.0–1.2) 0 0.0 (0.0–1.6)
Urticaria
All 1 0.3 (0.0–1.8) 3 1.3 (0.3–3.8)
Grade 3 0 0.0 (0.0–1.2) 0 0.0 (0.0–1.6)
a Includes the first three doses of hepatitis B vaccine and all three doses of
HPV-16/18 vaccine; TVC active-phase.
b n, total number of doses.
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(iii) Overall safety up to month 13. No SAEs were reported
up to month 7 of the study. Four women reported five SAEs
between month 7 and month 13. One woman in the
HepBHPV group experienced spontaneous abortion and en-
dometriosis, and another experienced Graves-Basedow’s dis-
ease. The woman with Graves-Basedow’s disease discontinued
the study because the investigator concluded that further vac-
cination was contraindicated. One woman in the HepB group
experienced type 1 diabetes mellitus, and another experienced
viral gastroenteritis. No SAEs were considered related to vac-
cination.
New-onset chronic diseases were reported during the whole
follow-up period to month 13 in one woman in the
HepBHPV group (Graves-Basedow’s disease [mentioned
above]) and in three women in the HepB group (type 1 dia-
betes mellitus [mentioned above], allergic dermatitis, and
urticaria). The cases of Graves-Basedow’s disease and type 1
diabetes mellitus were also considered to be potential NOADs.
No NOCDs or NOADs were considered related to vaccination.
Medically significant conditions were reported up to month 13
in 50.0% and 42.7% of women in the HepBHPV and HepB
groups, respectively. The only medically significant condition
reported by 5% of women was cystitis (8.1% of women in the
HepBHPV group and 8.0% of women in the HepB group).
No pregnancies were reported between months 0 to 7 of the
study. One pregnancy reported between months 7 and 13 by a
woman in the HepBHPV group resulted in a spontaneous
abortion. It was not considered related to vaccination, as men-
tioned above.
DISCUSSION
Overall, the immune responses to the hepatitis B vaccine
were similar in both study groups, regardless of coadminis-
tration of the HPV-16/18 vaccine. The findings of the study
indicate that the hepatitis B vaccine given in an accelerated
schedule may be coadministered with the HPV-16/18 AS04-
adjuvanted vaccine without compromising safety or immu-
nogenicity.
The coprimary endpoints of the study were seroprotection
rates and GMTs of anti-HBs antibodies at 1 month following
administration of the third dose of the hepatitis B vaccine.
High rates of seroprotection (96%) were achieved in both
groups and were similar to or somewhat higher than those
observed in other studies of the same accelerated schedule 1
month after the third vaccine dose (14, 17). One month after
the fourth dose of the hepatitis B vaccine, the seroprotection
rate was 100% in both groups.
Geometric mean titers of anti-HBs antibodies were similar
in both study groups although they tended to be slightly lower
in the HepBHPV group 1 month after the third vaccine dose.
This trend was reversed 1 month after the fourth dose. These
findings are unlikely to be clinically relevant, given the high
seroprotection rates observed. Similar results were observed in
a study of coadministration of the HPV-6/11/16/18 vaccine with
a hepatitis B vaccine administered in a standard schedule (31).
The authors of this study also concluded that the slightly lower
GMTs in the group who received both vaccines were unlikely
to be clinically significant. Antibody levels of 10 mIU/ml are
TABLE 4. Percentage of women reporting a solicited local or general symptom during the 7-day post-vaccination period following the fourth
dose of hepatitis B vaccine (TVC HepB fourth-dose)
Symptom Symptom grade
HepBHPV group
(n  74)a
HepB group
(n  75)a
No. of women
with symptom % of total (95% CI)
No. of women
with symptom % of total (95% CI)
Local symptoms
Pain All 36 48.6 (36.9–60.6) 44 58.7 (46.7–69.9)
Grade 3 2 2.7 (0.3–9.4) 0 0.0 (0.0–4.8)
Redness All 8 10.8 (4.8–20.2) 13 17.3 (9.6–27.8)
Grade 3 0 0.0 (0.0–4.9) 0 0.0 (0.0–4.8)
Swelling All 12 16.2 (8.7–26.6) 10 13.3 (6.6–23.2)
Grade 3 0 0.0 (0.0–4.9) 0 0.0 (0.0–4.8)
General symptoms
Arthralgia All 1 1.4 (0.0–7.3) 4 5.3 (1.5–13.1)
Grade 3 0 0.0 (0.0–4.9) 0 0.0 (0.0–4.8)
Fatigue All 26 35.1 (24.4–47.1) 34 45.3 (33.8–57.3)
Grade 3 1 1.4 (0.0–7.3) 0 0.0 (0.0–4.8)
Fever All 3 4.1 (0.8–11.4) 0 0.0 (0.0–4.8)
Grade 3 0 0.0 (0.0–4.9) 0 0.0 (0.0–4.8)
Gastrointestinal All 3 4.1 (0.8–11.4) 13 17.3 (9.6–27.8)
Grade 3 1 1.4 (0.0–7.3) 0 0.0 (0.0–4.8)
Headache All 21 28.4 (18.5–40.1) 25 33.3 (22.9–45.2)
Grade 3 1 1.4 (0.0–7.3) 0 0.0 (0.0–4.8)
Myalgia All 4 5.4 (1.5–13.3) 18 24.0 (14.9–35.3)
Grade 3 1 1.4 (0.0–7.3) 1 1.3 (0.0–7.2)
Rash All 1 1.4 (0.0–7.3) 0 0.0 (0.0–4.8)
Grade 3 0 0.0 (0.0–4.9) 0 0.0 (0.0–4.8)
Urticaria All 0 0.0 (0.0–4.9) 0 0.0 (0.0–4.8)
Grade 3 0 0.0 (0.0–4.9) 0 0.0 (0.0–4.8)
a n, total number women.
1516 LEROUX-ROELS CLIN. VACCINE IMMUNOL.
 o
n
 April 10, 2012 by UNIVERSITEIT G
ENT/UZG
ENT
http://cvi.asm
.org/
D
ow
nloaded from
 
generally accepted as offering protection against clinically sig-
nificant hepatitis B infection (15, 18, 33), and geometric mean
titers were well above this level in the present study in both
study groups.
All initially seronegative women who received the HPV-
16/18 vaccine seroconverted for HPV-16 and HPV-18, and
100% remained so up to 1 month after the third vaccine dose.
Peak GMT levels were similar to those observed in a large
phase III study in which efficacy against cervical lesions asso-
ciated with HPV-16/18 and some nonvaccine oncogenic types
has been shown (23). Furthermore, antibody levels were sim-
ilar to those observed at the same time point in a long-term
study in which sustained immunogenicity and efficacy have
been shown up to 6.4 years (12).
Two other studies have investigated coadministration of the
HPV-16/18 AS04-adjuvanted vaccine with other vaccines,
i.e., a combined hepatitis A and B vaccine and a diphtheria-
tetanus-pertussis-inactivated polio vaccine. Coadministration
of these vaccines did not indicate any interference with the
immune response of either vaccine (9, 24).
In the present study, both vaccines had an acceptable safety
profile. Few SAEs occurred, and none was considered related
to vaccination. Two potential NOADs, Graves-Basedow’s dis-
ease and type 1 diabetes mellitus, occurred during the study. It
is worth noting that the investigators caring for these women
considered that the conditions might have been present but
undiagnosed prior to vaccination. The safety profiles of the
hepatitis B vaccine were similar regardless of whether it was
administered alone or with the HPV-16/18 vaccine. The hep-
atitis B vaccine used in the study has been widely available for
many years and has a well-documented safety profile when
used both in the standard schedule and the accelerated sched-
ule (1, 16, 26). The HPV-16/18 vaccine also exhibited a safety
profile similar to that observed in other studies (13, 22) and in
pooled analyses (5, 29).
The study had some limitations. Data analyses were descrip-
tive, and the study was not statistically powered to perform
noninferiority or equivalence testing between the two study
groups. In addition, there was no group who received the
HPV-16/18 vaccine alone, meaning that the impact of coad-
ministration of the hepatitis B vaccine on the immunogenicity
of the HPV-16/18 vaccine could not be established in this
study. However, in a previous study of coadministration of the
HPV-16/18 and hepatitis A/B vaccines, the HPV-16/18 im-
mune response was statistically noninferior for coadministra-
tion of the two vaccines compared with administration of the
HPV-16/18 vaccine alone (24).
Although infant immunization against hepatitis B has now
been introduced in many countries, a large proportion of the
population remains unvaccinated because they were born be-
fore the mass vaccination program was introduced, and thus a
considerable burden of disease may remain. Catch-up pro-
grams may be needed in some countries to hasten the spread
of population-based immunity (33). The key target population
for the HPV vaccine is young adolescent girls. However, many
countries have also implemented catch-up programs in older
girls and young women (34). Because the hepatitis B vaccine
was introduced into infant immunization programs only rela-
tively recently in many countries or has not yet been intro-
duced, many young women receiving the HPV vaccine in a
catch-up program may also require the hepatitis B vaccine. If
young women receiving both vaccines are in a high-risk group
for acquiring hepatitis B (e.g., travelers, drug users, or sex
workers), they are likely to receive the vaccine in an acceler-
ated schedule.
In conclusion, data from this study show that coadministra-
tion of the HPV-16/18 AS04-adjuvanted vaccine appears not to
affect the immunogenicity and safety of the hepatitis B vaccine
administered in adult women in an accelerated schedule.
Women at high risk for hepatitis B who require the accelerated
vaccination schedule need not delay either their hepatitis B or
their HPV vaccination course.
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